VA
REGN icon

Vident Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

Vident Advisory’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.66M Buy
3,449
+781
+29% +$598K 0.02% 539
2025
Q4 		$2.06M Sell
2,668
-17
-0.6% -$11.5K 0.02% 575
2025
Q3 		$1.51M Buy
2,685
+236
+10% +$133K 0.01% 662
2025
Q2 		$1.29M Sell
2,449
-173
-7% -$96.6K 0.01% 641
2025
Q1 		$1.66M Sell
2,622
-2,055
-44% -$1.41M 0.02% 544
2024
Q4 		$3.33M Buy
4,677
+3,254
+229% +$2.73M 0.06% 296
2024
Q3 		$1.5M Sell
1,423
-4,449
-76% -$4.95M 0.04% 494
2024
Q2 		$6.17M Sell
5,872
-18,860
-76% -$18.3M 0.17% 117
2024
Q1 		$23.8M Buy
24,732
+4,860
+24% +$4.62M 0.5% 35
2023
Q4 		$17.5M Sell
19,872
-1,990
-9% -$1.64M 0.44% 46
2023
Q3 		$18M Buy
+21,862
New +$17.2M 0.56% 32

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vident Advisory's REGN Position: Q1 2026 in Review

Vident Advisory increased its Regeneron Pharmaceuticals (REGN) stake by 29% in Q1 2026, buying an estimated $598K and bringing the position to 3,449 shares worth $2.66M. The position accounts for 0.02% of the portfolio, ranked #539.

Vident Advisory first reported a position in REGN in Q3 2023 and has held it in 11 quarters since. The position peaked at $23.8M in Q1 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Vident Advisory held 3,449 shares of Regeneron Pharmaceuticals worth $2.66M as of Q1 2026.
  • Vident Advisory bought 781 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $598K.
  • Regeneron Pharmaceuticals made up 0.02% of Vident Advisory's portfolio in Q1 2026, its #539 holding.
  • Vident Advisory first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Vident Advisory's Regeneron Pharmaceuticals position peaked at $23.8M in Q1 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.